Cargando…

Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis

BACKGROUND: Mounting evidence has suggested that plasminogen activator inhibitor-1 (PAI-1) is a candidate for increased risk of diabetic retinopathy. Studies have reported that insertion/deletion polymorphism in the PAI-1 gene may influence the risk of this disease. To comprehensively address this i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Tengyue, Pang, Chong, Li, Ningdong, Zhou, Elaine, Zhao, Kanxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565939/ https://www.ncbi.nlm.nih.gov/pubmed/23281898 http://dx.doi.org/10.1186/1741-7015-11-1

Ejemplares similares

The 4G/5G polymorphism of plasminogen activator inhibitor type 1 is a predictor of allergic cough
por: Tang, Rui, et al.
Publicado: (2023)

Association between Plasminogen Activator Inhibitor-1 -675 4G/5G Polymorphism and Sepsis: A Meta-Analysis
por: Li, Li, et al.
Publicado: (2013)

Meta-Analysis of the Association between Plasminogen Activator Inhibitor-1 4G/5G Polymorphism and Recurrent Pregnancy Loss
por: Li, Xuejiao, et al.
Publicado: (2015)

Plasminogen Activator Inhibitor-1 4G/5G (rs1799889) Polymorphism in Chinese Patients with Diabetes Mellitus and Hypertension
por: Wang, Ziran, et al.
Publicado: (2023)

Association of Plasminogen Activator Inhibitor-Type 1 (-675 4G/5G) Polymorphism with Pre-Eclampsia: Systematic Review
por: Morgan, Jessie A., et al.
Publicado: (2013)

The −675 4G/5G Polymorphism in Plasminogen Activator Inhibitor-1 Gene Is Associated with Risk of Asthma: A Meta-Analysis
por: Nie, Wei, et al.
Publicado: (2012)

Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma
por: Mossböck, Georg, et al.
Publicado: (2008)

The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease
por: Katko, Monika, et al.
Publicado: (2021)

Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian subjects
por: Al-Hamodi, Zaid H., et al.
Publicado: (2012)

Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Presenting as Recurrent Ischemic Stroke: The Microthrombi Shower
por: Dayco, John, et al.
Publicado: (2022)

Plasminogen Activator Inhibitor-1 4G/5G Gene Polymorphism and Coronary Artery Disease in the Chinese Han Population: A Meta-Analysis
por: Li, Yan-yan
Publicado: (2012)

Plasminogen activator inhibitor-1 4G/5G polymorphism and dyslipidemia with branch retinal artery occlusion in a young lady
por: Kurtul, Bengi Ece, et al.
Publicado: (2020)

Association of the 4 g/5 g polymorphism of plasminogen activator inhibitor-1 gene with sudden sensorineural hearing loss. A case control study
por: Cho, Seong Ho, et al.
Publicado: (2012)

Association of OPA1 Polymorphisms with NTG and HTG: A Meta-Analysis
por: Guo, Yatu, et al.
Publicado: (2012)

Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease.
por: Song, J., et al.
Publicado: (2000)

Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis
por: Zhang, Xin, et al.
Publicado: (2020)

Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study
por: Yousef, Aly A, et al.
Publicado: (2020)

Association of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene -675 4G/5G and -844 A/G Promoter Polymorphism with Risk of Keloid in a Chinese Han Population
por: Wang, Yongjie, et al.
Publicado: (2014)

Role of 4G/5G plasminogen activator inhibitor-1 (PAI-1) gene polymorphism and the PAI-1 plasma levels in the outcome of patients with severe sepsis
por: Lorente, L, et al.
Publicado: (2009)

Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study [Corrigendum]
Publicado: (2021)

PAI-1 -675 4G/5G Polymorphism in Association with Diabetes and Diabetic Complications Susceptibility: a Meta-Analysis Study
por: Xu, Kuanfeng, et al.
Publicado: (2013)

Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
por: Jasmiad, Nurbadriah binti, et al.
Publicado: (2022)

Effect of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms on Susceptibility to Type 2 Diabetes in Malaysian Subjects
por: Al-Hamodi, Zaid, et al.
Publicado: (2012)

Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in Serbian population
por: Joksic, Ivana, et al.
Publicado: (2020)

Polymorphism 2184A/G in the AGER gene is not associated with diabetic retinopathy in Han Chinese patients with type 2 diabetes
por: Li, Jian, et al.
Publicado: (2016)

Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding.
por: Kim, Hong-Soo, et al.
Publicado: (2003)

4G/5G Variant of Plasminogen Activator Inhibitor-1 Gene and Severe Pregnancy-Induced Hypertension: Subgroup Analyses of Variants of Angiotensinogen and Endothelial Nitric Oxide Synthase
por: Kobashi, Gen, et al.
Publicado: (2009)

Meta-Analysis of TNF 308 G/A Polymorphism and Type 2 Diabetes Mellitus
por: Feng, Ren-Nan, et al.
Publicado: (2011)

PAI-1 4G/5G Polymorphism Contributes to Cancer Susceptibility: Evidence from Meta-Analysis
por: Wang, Shangqian, et al.
Publicado: (2013)

Association of Monocyte Chemoattractant Protein-1 (MCP-1) 2518A/G Polymorphism with Proliferative Diabetic Retinopathy in Korean Type 2 Diabetes
por: Jeon, Hyun Jeong, et al.
Publicado: (2013)

PSUN171 CORRELATIONS BETWEEN SERUM AND TEAR PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) AND TISSUE PLASMINOGEN ACTIVATOR (tPA) IN PATIENTS WITH DIABETIC RETINOPATHY
por: Jasmiad, Nurbadriah, et al.
Publicado: (2022)

Evaluation of Serum Fibrinogen, Plasminogen, α2-Anti-Plasmin, and Plasminogen Activator Inhibitor Levels (PAI) and Their Correlation with Presence of Retinopathy in Patients with Type 1 DM
por: Polat, Sefika Burcak, et al.
Publicado: (2014)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

The association of TNF-α −308G/A and −238G/A polymorphisms with type 2 diabetes mellitus: a meta-analysis
por: Guo, Xiaoliang, et al.
Publicado: (2019)

IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan
por: Keshavarzi, Fatemeh, et al.
Publicado: (2019)

Meta-Analysis on the Association of ALDH2 Polymorphisms and Type 2 Diabetic Mellitus, Diabetic Retinopathy
por: Li, Guang-Yi, et al.
Publicado: (2017)

Plasma Plasminogen Activator Inhibitor-1 Is Associated with End-Stage Proliferative Diabetic Retinopathy in the Northern Chinese Han Population
por: Zhong, Ze-Long, et al.
Publicado: (2012)

Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
por: Al-Hamodi, Zaid, et al.
Publicado: (2011)

WRN polymorphisms affect expression levels of plasminogen activator inhibitor type 1 in cultured fibroblasts
por: Castro, Elena, et al.
Publicado: (2008)

CTLA-4 (+49A/G) Polymorphism and Type-1 Diabetes in Turkish Children
por: Çelmeli, Fatih, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5n32cnhtuhfj94lghar7i65nhu